Angiotensin II Receptor Blockade Physiological and Clinical Implications
The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemi...
Gespeichert in:
| Weitere Verfasser: | , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Springer US
1998
|
| Schriftenreihe: | Progress in Experimental Cardiology
2 |
| Schlagworte: | |
| Online-Zugang: | DE-355 URL des Erstveröffentlichers |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046143585 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1998 xx o|||| 00||| eng d | ||
| 020 | |a 9781461557432 |9 978-1-4615-5743-2 | ||
| 024 | 7 | |a 10.1007/978-1-4615-5743-2 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-5743-2 | ||
| 035 | |a (OCoLC)1118997805 | ||
| 035 | |a (DE-599)BVBBV046143585 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.12 |2 23 | |
| 245 | 1 | 0 | |a Angiotensin II Receptor Blockade Physiological and Clinical Implications |c edited by Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish |
| 264 | 1 | |a Boston, MA |b Springer US |c 1998 | |
| 300 | |a 1 Online-Ressource (XLIII, 588 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Progress in Experimental Cardiology |v 2 | |
| 520 | |a The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential | ||
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Cardiology | |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Angiotensin-II-Blocker |0 (DE-588)4368837-8 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)1071861417 |a Konferenzschrift |y 1996 |z Winnipeg Manitoba |2 gnd-content | |
| 689 | 0 | 0 | |a Angiotensin-II-Blocker |0 (DE-588)4368837-8 |D s |
| 689 | 0 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Dhalla, Naranjan S. |4 edt | |
| 700 | 1 | |a Zahradka, Peter |4 edt | |
| 700 | 1 | |a Dixon, Ian M. C. |4 edt | |
| 700 | 1 | |a Beamish, Robert E. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792381471 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461376316 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461557449 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-5743-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031523770 | |
| 966 | e | |u https://doi.org/10.1007/978-1-4615-5743-2 |l DE-355 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1819307120374317056 |
|---|---|
| any_adam_object | |
| author2 | Dhalla, Naranjan S. Zahradka, Peter Dixon, Ian M. C. Beamish, Robert E. |
| author2_role | edt edt edt edt |
| author2_variant | n s d ns nsd p z pz i m c d imc imcd r e b re reb |
| author_facet | Dhalla, Naranjan S. Zahradka, Peter Dixon, Ian M. C. Beamish, Robert E. |
| building | Verbundindex |
| bvnumber | BV046143585 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-5743-2 (OCoLC)1118997805 (DE-599)BVBBV046143585 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4615-5743-2 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03676nam a2200553zcb4500</leader><controlfield tag="001">BV046143585</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1998 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461557432</subfield><subfield code="9">978-1-4615-5743-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-5743-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-5743-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118997805</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046143585</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Angiotensin II Receptor Blockade Physiological and Clinical Implications</subfield><subfield code="c">edited by Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XLIII, 588 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Progress in Experimental Cardiology</subfield><subfield code="v">2</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Angiotensin-II-Blocker</subfield><subfield code="0">(DE-588)4368837-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1996</subfield><subfield code="z">Winnipeg Manitoba</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Angiotensin-II-Blocker</subfield><subfield code="0">(DE-588)4368837-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dhalla, Naranjan S.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zahradka, Peter</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dixon, Ian M. C.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beamish, Robert E.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792381471</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461376316</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461557449</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-5743-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031523770</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-5743-2</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)1071861417 Konferenzschrift 1996 Winnipeg Manitoba gnd-content |
| genre_facet | Konferenzschrift 1996 Winnipeg Manitoba |
| id | DE-604.BV046143585 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-24T07:47:54Z |
| institution | BVB |
| isbn | 9781461557432 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031523770 |
| oclc_num | 1118997805 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XLIII, 588 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Springer US |
| record_format | marc |
| series2 | Progress in Experimental Cardiology |
| spelling | Angiotensin II Receptor Blockade Physiological and Clinical Implications edited by Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish Boston, MA Springer US 1998 1 Online-Ressource (XLIII, 588 p) txt rdacontent c rdamedia cr rdacarrier Progress in Experimental Cardiology 2 The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential Cardiology Pharmakologie (DE-588)4045687-0 gnd rswk-swf Angiotensin-II-Blocker (DE-588)4368837-8 gnd rswk-swf 1\p (DE-588)1071861417 Konferenzschrift 1996 Winnipeg Manitoba gnd-content Angiotensin-II-Blocker (DE-588)4368837-8 s Pharmakologie (DE-588)4045687-0 s 2\p DE-604 Dhalla, Naranjan S. edt Zahradka, Peter edt Dixon, Ian M. C. edt Beamish, Robert E. edt Erscheint auch als Druck-Ausgabe 9780792381471 Erscheint auch als Druck-Ausgabe 9781461376316 Erscheint auch als Druck-Ausgabe 9781461557449 https://doi.org/10.1007/978-1-4615-5743-2 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Angiotensin II Receptor Blockade Physiological and Clinical Implications Cardiology Pharmakologie (DE-588)4045687-0 gnd Angiotensin-II-Blocker (DE-588)4368837-8 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4368837-8 (DE-588)1071861417 |
| title | Angiotensin II Receptor Blockade Physiological and Clinical Implications |
| title_auth | Angiotensin II Receptor Blockade Physiological and Clinical Implications |
| title_exact_search | Angiotensin II Receptor Blockade Physiological and Clinical Implications |
| title_full | Angiotensin II Receptor Blockade Physiological and Clinical Implications edited by Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish |
| title_fullStr | Angiotensin II Receptor Blockade Physiological and Clinical Implications edited by Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish |
| title_full_unstemmed | Angiotensin II Receptor Blockade Physiological and Clinical Implications edited by Naranjan S. Dhalla, Peter Zahradka, Ian M. C. Dixon, Robert E. Beamish |
| title_short | Angiotensin II Receptor Blockade Physiological and Clinical Implications |
| title_sort | angiotensin ii receptor blockade physiological and clinical implications |
| topic | Cardiology Pharmakologie (DE-588)4045687-0 gnd Angiotensin-II-Blocker (DE-588)4368837-8 gnd |
| topic_facet | Cardiology Pharmakologie Angiotensin-II-Blocker Konferenzschrift 1996 Winnipeg Manitoba |
| url | https://doi.org/10.1007/978-1-4615-5743-2 |
| work_keys_str_mv | AT dhallanaranjans angiotensiniireceptorblockadephysiologicalandclinicalimplications AT zahradkapeter angiotensiniireceptorblockadephysiologicalandclinicalimplications AT dixonianmc angiotensiniireceptorblockadephysiologicalandclinicalimplications AT beamishroberte angiotensiniireceptorblockadephysiologicalandclinicalimplications |